Evotec Posts €426M Net Loss as Revenue Slides in 2024
Evotec's 2024 results show deepening losses and falling revenue, putting the Hamburg biotech under intense investor scrutiny.
Evotec just handed traders a rough scorecard. The Hamburg-based drug discovery company posted full-year 2024 revenue of €797.0 million — and that number is heading in the wrong direction. Declining top-line figures combined with a widening EBITDA loss of €55.8 million tell you the core business is burning more than it's earning right now.
The net loss is the number that stings most: €426.6 million in the red. That's not a rounding error — that's a structural problem that demands answers from management. When losses balloon at that scale, every investor needs to ask whether the balance sheet can absorb more pain before a turnaround kicks in.
Read more Why Falling Oil Prices Won't Bring Cheaper Gas at the Pump →
Here's the tradeable angle: Evotec still carries a significant commercial base, which means the revenue infrastructure exists. The question isn't whether the company has customers — it's whether leadership can stop the bleeding on the cost side and restore operating leverage. If they can't show early signs of improvement in upcoming quarters, the stock faces serious downside pressure.
Right now, sentiment is squarely in wait-and-see mode. Traders are watching the next reporting period like a hawk, looking for any positive movement in operating metrics. Until those numbers show a credible path toward profitability, this is a high-risk hold at best.
Continue reading at AD HOC NEWS.
